



**ISSN : 2347-2251**  
**Indo-American Journal of  
Pharma and Bio Sciences**



[www.iajpb.com](http://www.iajpb.com)

[iajpb.editor@gmail.com](mailto:iajpb.editor@gmail.com)  
[editor@iajpb.com](mailto:editor@iajpb.com)



# Curcumin as a Natural Neuroprotective Agent: A Multifaceted Approach to Cognitive Well-being

Ch. Devadasu<sup>1</sup>, R.V.S.Mounica<sup>2</sup>, K.Srikanth Kumar<sup>3</sup>, J.Dharuman<sup>4</sup>

1. Assistant Professor, Department of Pharm. Analysis, QIS College of pharmacy, Ongole, AP

2. Assistant Professor, Department of pharm. analysis, QIS College of pharmacy, Ongole, AP

3. Associate Professor, Department of pharam. CHEMISTRY, QIS College of pharmacy, Ongole, AP

4. Associate Professor, Department of Pharm. chemistry QIS College of pharmacy, Ongole, AP

\*Corresponding Author

**Ch. Devadasu**

**devadasuch@gmail.com**

## Abstract

In Southeast Asia, turmeric (*Curcuma longa*) is widely used as a coloring agent and spice. Because of its antiseptic, antibacterial, and anti-inflammatory qualities, turmeric is used as a traditional treatment for rheumatism, diabetic sores, cough, and liver problems. Turmeric and its components have been the subject of much research into their pharmacological effects over the last several decades. Turmeric's primary ingredient, curcumin, has been shown to have anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antibacterial properties. There is no long-term treatment for neurodegenerative diseases, which cause the loss of synapses and functioning neurons in the brain. Neurological problems associated with aging are influenced by inflammation and oxidative damage. Various neurological problems may be prevented by antioxidants. According to recent research, curcumin and turmeric both offer neuroprotective and cognitive-enhancing qualities that aid in the prevention of neurodegenerative illnesses like Parkinson's and Alzheimer's. Turmeric and curcumin have been shown in several experimental tests to have anti-aging and antioxidant qualities. Curcumin may be a viable medication choice for the prevention of neurodegenerative illnesses as several studies have shown that it functions as an effective barrier against neurological disorders. Presenting the most recent research on the neuroprotective benefits of turmeric and curcumin was the goal of this review.

## 1. Introduction

Turmeric is a perennial herbaceous rhizome plant that is a member of the Zingiberaceae family, which includes ginger. Turmeric is believed to have originated in the tropical region of Southeast Asia, most likely India, however its exact origin is unknown. It is now grown in Africa, China, Japan, Thailand, and Indonesia. In cuisine, turmeric is an active component of mustard and curries (Kim et al., 2014; Yuliani et al., 2019). Additionally, it is utilized as a food preservative, flavor enhancer, and coloring agent. One of the most studied species of medicinal plants, according to reports (Jessica Elizabeth et al., 2017). Turmeric is a plant with a funnel shape with bracts that are green and white in color. It bears yellow blooms that are 5 to 5.5 cm long and fruitless. Various turmeric genotypes are said to be abundant in essential oils (Akbar et al., 2015; Azmi et al., 2016). Because of its many pharmacological properties, turmeric has gained a

lot

of

Many age-related neurodegenerative disorders are characterized by oxidative damage, inflammation, and protein coagulation. In addition to its anti-inflammatory and antioxidant qualities, curcumin has been shown to have a neuroprotective role as an anti-coagulating agent



global interest in recent years. According to Kuwatada et al. (2017), turmeric has anti-inflammatory, anticarcinogenic, antibacterial, and antimutagenic qualities. The Ayurvedic, Unani, and Siddha medical systems all utilize turmeric as a traditional treatment (Selvi et al., 2015). It may be used medicinally to treat a variety of illnesses, including parasite infections, skin conditions, ulcers, and immune system disorders. Additionally, it is utilized to treat the flu and cold (Siviero et al., 2015). It possesses anti-aging (Vaughn et al., 2016), anti-inflammatory, antiproliferative, and antioxidant qualities (Arya et al., 2015; Lim and Han, 2018). Additionally, it has been shown to have anti-tumor (Vemuri et al., 2017), anti-venom (Singh et al., 2017), and anti-protozoan (Llurba- Montesino et al., 2015) properties. In addition to being a mosquito repellent, turmeric's essential oil and alcoholic and aqueous extracts have shown exceptional pesticidal qualities (Dosoky and Setzer, 2018).

for proteins (Maiti and Dunbar, 2018). Curcumin is the preferred neuroprotective medication for a variety of neurological problems, such as neurodegenerative diseases, stroke, and aging, due to its lengthy history of use, cheap cost, oral safety, pluripotency, and



neuroprotective properties (Tamagno et al., 2005). Numerous research have shown that curcumin and turmeric reduce dementia symptoms (Ahmed and Gilani, 2014; Samy et al., 2016). However, curcumin's bioavailability is limited by its quick metabolic breakdown, rapid systemic clearance, and poor absorption, which limits its huge therapeutic potential (Anand et al., 2007; Yu and Huang, 2012; Prasad et al., 2014; Liu et al., 2016). A variety of clinical symptoms, including memory loss, language difficulties, and behavioral abnormalities that interfere with day-to-day activities, are indicative of dementia. Alzheimer's disease (AD) is thought to be the most common kind of dementia, followed by dementia with Lewy bodies (DLB), mixed dementia (MD), and vascular dementia (VD). Given that the world's population is aging quickly and that dementia has a substantial social and financial impact, it is considered a worldwide issue (Robinson et al., 2015). Acetylcholine (ACh) insufficiency and free radical accumulation in Alzheimer's patients' brains are recognized as contributing factors to dementia and cognitive issues. Impaired cholinergic neurotransmission is caused by processes that include a cholinergic deficit and a disruption in the equilibrium between the quantity of free radicals and the antioxidant (AO) defense system (Ovais et al., 2018; Abu Bakar et al., 2020). Because turmeric is widely used as a culinary spice in Southeast Asian nations, epidemiologic studies have shown that the prevalence of AD is 4.4 times lower there than in the West (Mishra and Palanivelu, 2008; Latif et al., 2019). With an emphasis on its potential as a treatment for Parkinson's and Alzheimer's illnesses, this review aims to highlight turmeric's neuroprotective effect in neurodegenerative disorders.

## 2. Chemical constituents of turmeric

Turmeric root or rhizome is commonly used in traditional medicine. A large number of different constituents have been identified in turmeric. Polyphenolic curcuminoids constitute the main group of turmeric's bioactive compounds which include curcumin (diferuloylmethane), bisdemethoxycurcumin, demethoxycurcumin, and cyclocurcumin. The yellow-pigmented curcuminoids contain 85% curcumin, 10% demethoxycurcumin and 5% bisdemethoxycurcumin. Curcumin is a well-studied compound of turmeric. Turmeric also contains sesquiterpenes (turmerone, zingiberone, atlantone, germacrone, turmeronol, and bisabolene), proteins, carbohydrates, resins, and caffeic acid (Jurenka, 2009; Dosoky and Setzer, 2018). Additionally, turmeric has been reported to contain a variety of biochemical compounds involved in a variety of biological functions as summarized in

Table 1.

## 3. Curcumin: the most important bioactive compound of turmeric

Curcumin is a widely studied nutraceutical isolated from the rhizomes of turmeric. It was first discovered about two centuries ago by Vogel and Pelletier, the scientists of Harvard College laboratory (Gupta *et al.*, 2012). The active principle of turmeric is curcumin that is a low molecular weight polyphenol with a bright yellow colour. Curcumin is a highly pleiotropic molecule. This polyphenol has been shown to possess anti-inflammatory, hypoglycaemic, antioxidant, wound-healing, and antimicrobial, antiangiogenic, antimutagenic, and antiplatelet aggregation activities. Curcumin is also reported to have nephroprotective activity and shown to work as a therapeutic agent against myocardial infarction, cystic fibrosis, atherosclerosis, neurodegenerative diseases, cancer, rheumatoid inflammation, ocular diseases, osteoporosis, hypertension, chronic kidney diseases, diabetes, chronic inflammation, infection and various skin diseases (Maiti and Dunbar, 2018). Some populations having traditional use of a curcumin-rich diet have shown a low incidence of AD and their good cognitive ability has been associated with the use of curry, a routine food that contains turmeric which is a source of curcumin (Nakayama *et al.*, 2014). In vivo experiments on the dementia rat model have shown the efficacy of curcumin for the treatment of memory impairment and proved to be a safeguard against oxidative damage (Yaari *et al.*, 2008; Kumar *et al.*, 2009; Agrawal *et al.*, 2010). Despite its demonstrated safety and efficacy, the use of curcumin in chemopreventive or therapeutic settings has been limited by its short biological half-life and low bioavailability. Low serum and tissue levels of curcumin irrespective of the route of administration, rapid metabolism and elimination are some of the major factors curtailing the bioavailability of curcumin. Different studies have also shown that curcumin was poorly bioavailable on oral administration (Ravindranath and Chandrasekhara, 1980; Perkins *et al.*, 2002; Jamwal,



Table 1. Chemical constituents of turmeric and their effect on the brain

Turmeric Compounds	Effect on brain
Alpha linolenic acid (omega-3 fatty acid)	Antioxidant and anti-inflammatory; increases ACh production; increases glucose absorption by cell; anti-AD; energy production and signaling in brain cells (Kaplan <i>et al.</i> , 2017; Ajith, 2018).
Calebin-A	Antioxidant and anti-inflammatory; neuroprotection (Novaes <i>et al.</i> , 2017).
Cinnamic acid	Anti-inflammatory (Qabaha <i>et al.</i> , 2017); neuroprotection (Prorok <i>et al.</i> , 2019).
Ferulic acid	Antioxidant; AChE inhibition (Kaur <i>et al.</i> , 2018).
Vanillic acid	Antioxidant; anti-inflammatory (Kaur <i>et al.</i> , 2018).
Magnesium	Anti-inflammatory; antioxidant; lowers the rate of dementia and vascular dementia (Novaes <i>et al.</i> , 2017).
Thiamine (vitamin B1)	Deficiency of thiamine causes confusion and memory loss; glucose absorption in brain and nervous system cells (Kaur <i>et al.</i> , 2018; Nedeljković <i>et al.</i> , 2018).
Riboflavin (vitamin B2)	Detoxification and excess metal chelation; neuroprotective effects in some neurological conditions (PD, multiple sclerosis, migraine); antioxidant; myelin formation; mitochondrial function; iron metabolism (Nedeljković <i>et al.</i> , 2018).
Niacin (vitamin B3)	Essential for the production of cell energy; antioxidant; stimulates mitochondria; increases ATP production; neuronal maturation and neuroprotection (Fricker <i>et al.</i> , 2018).
Pyridoxine (vitamin B6)	Rate-limiting cofactor in the production of neurotransmitters; neuroprotection (Nedeljković <i>et al.</i> , 2018).
Folic Acid (folate; vitamin B9)	Anti-AD; promotes energy production by mitochondria; memory enhancement and cognitive improvement; anti-inflammatory (Chen <i>et al.</i> , 2016; Cianciulli <i>et al.</i> , 2016).
Vitamin C	Antioxidant; enhances the immune system; reduces glutamate-mediated excitotoxicity; neuronal differentiation and maturation; modulation of neurotransmission; increase ATP production (Man Anh <i>et al.</i> , 2019).
Vitamin E	Neuroprotective; anti-inflammatory; antioxidant; hypocholesterolemic; cognitive enhancement; reduces the progression of AD (Lloret <i>et al.</i> , 2019).
Quercetin	Antioxidant; anti-inflammatory; protection of mitochondria; elimination of extra iron; inhibition of AD causing TNF- $\alpha$ and COX-2 (Khan <i>et al.</i> , 2018).
Resveratrol	Antioxidant; protection against neurodegenerative diseases and assembly of A $\beta$ protein by activating SIRT1 longevity gene (Gomes <i>et al.</i> , 2018); prevention of brain cell death in hippocampus (Kodali <i>et al.</i> , 2015); inhibition of inflammatory enzymes (de Sá Coutinho <i>et al.</i> , 2018); protection of brain cells from injury by stimulating vitagenes; clearance of $\alpha$ -synuclein (Guo <i>et al.</i> , 2016); protects from metabolic stress (Palomera-Avalos <i>et al.</i> , 2017).
Turmerones	Blocks A $\beta$ production and aggregation (Maiti and Dunbar, 2018).
Xanthorrhizol	Neuroprotection; antioxidant; anti-inflammatory; anti-A $\beta$ (Lim and Han, 2018).
Zingiberene	anti-A $\beta$ ; prevents the formation of advanced glycation end products (AGEs) in brain cells (Lim and Han, 2018).

#### 4. Neurodegenerative diseases and neuroprotection




Figure 1. The causes of neurodegeneration including neuronal death gene mutation, genetic factors, environmental factors and dysfunctioning of cells involving protein coagulation and then neuronal death with clinical expression of neurodegenerative diseases.

The etiology of neurodegeneration involves various environmental and genetic factors, genetic mutations,



pathophysiological processes of neuronal death, and dysfunction of glial cells (Figure 1). Degeneration of the central nervous system leads to cell death, failure of axon regeneration, demyelination, and in general the structural and functional neuronal deficits. All these conditions partly or completely, single or combined, genetic or attained, are demonstrated in neurological disorders, collectively known as neurodegenerative disorders. These disorders are harmful to the normal functioning of the brain and cause progressive deterioration as they are one of the leading causes of disability and mortality. There are various neurodegenerative disorders but special attention has been given to AD, Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), and Huntington disease (HD) (Hussain *et al.*, 2018). Although there are hundreds of neurodegenerative diseases, their classification is quite challenging in view of their overlapping clinical and pathological symptoms. Neurodegenerative diseases may be grouped into a disease of ganglion, cortex, brainstem, cerebellum or spinal cord. Among neurodegenerative diseases, AD is the sixth leading cause of death in the world (McMackin *et al.*, 2019; Weis *et al.*, 2019). Studies have shown that

damage to protein, lipids, and DNA with a decrease in antioxidant levels (Lee *et al.*, 2012; Höhn and Grune, 2013). In neurodegenerative diseases, the modification of oxidative proteins occurs at a low level that accumulates in a variety of cells and tissues (Zhang, 2013).

The term neuroprotection means the ability to defend the central nervous system from an acute neural injury such as stroke or trauma, and chronic neurodegenerative disorders like AD and PD. In this respect, herbal medicines may play a valuable role in the prevention of neurodegenerative diseases with a healthy lifestyle including good physical activity and dietary habits. The medicinal use of plant organs like roots, stem, leaves, flowers, fruits, and seeds in herbal medicine is a complementary and alternative method of treatment. The plant products contain a complex mixture of phytochemicals compounds (Nour *et al.*, 2014; Fazel Nabavi *et al.*, 2016; Spagnuolo *et al.*, 2016).

## 5. Potential therapeutic targets in

The neurodegenerative disorders constitute the most common forms of dementia but the identification of suitable therapeutic targets is

restricted due to a variety of aetiologies involved. Except for the inherited AD and VD, the underlying aetiologies are still unidentified for most dementia disorders. However, multiple pathologies leading to potential therapeutic targets include amyloid- beta ( $A\beta$ ) and abnormal tau proteins for AD, angiogenic and ischemic lesions for VD, and  $\alpha$ -synucleinopathy for LBD, primarily cholinergic neurotransmitter defects, inflammatory pathways, oxidative stress, apoptosis, and diminished neuroplasticity (Kumar and Singh, 2015; Zhou *et al.*, 2016). Other therapeutic targets include the cholinesterase inhibitors (ChEIs) which act as anti-AChE thereby enhancing the cholinergic neurotransmission by increasing the ACh level at the synaptic junction; secretase inhibitors including  $\beta$ -secretase and  $\gamma$ -secretase which prevent the deposition of the amyloid plaques in brain by restricting the synthesis of  $A\beta_{1-42}$  fragment from amyloid precursor protein (APP); anti-inflammatory drugs including cyclooxygenase (COX) inhibitors which act by decreasing the neurotoxic COX level thereby reducing the inflammation of brain tissue, and antioxidants including the drugs which combat the free radicals which are considered as one of the main factors that oxidatively injure the brain tissue (Natarajan *et al.*, 2013).

## 6. Turmeric and neurological disorders

Neurological disorders are defined as the disorders of the peripheral and central nervous system including the brain, spinal cord, nerves, autonomic nervous system, and neuromuscular junction, muscles leading to AD, PD, epilepsy, migraine, and brain tumours (Khan *et al.*, 2018). The use of turmeric in medicine is due to its chemical composition. Turmeric contains almost 235 compounds among which curcuminoids are the most bioactive compounds containing curcumin. A study on turmeric consumption and cognitive function in Asian people showed that the elderly Asians who use curry (once a month or more) containing turmeric had a superior cognitive function as compared to those who rarely consume curry (less than one in six months). They have higher Mini-Mental State Examination (MMSE), which proves their superior cognitive function (Ng *et al.*, 2006; Suryanarayana *et al.*, 2007; Yao and Xue, 2014). Turmeric was found effective for behavioural and psychological symptoms of dementia (BPSD) treatment including hallucination, apathy, delusions, agitation, anxiety, and depression. In a clinical study on turmeric administration, a decrease in the acuity of symptoms was observed



(Huang *et al.*, 2012).

There are many molecular targets like transcription factors, kinases, inflammatory cytokines, antioxidants and growth factors which are modulated and communicated by curcumin. All these actions of curcumin are due to its neuroprotective activity. Various pathways in different types of cells of the nervous system like neurons, astrocytes, and microglia (Lavoie *et al.*, 2009; Maiti and Dunbar, 2018) have explained this supportive effect of curcumin. The curcumin was observed to possess a neuroprotective function in the primary cell culture of different areas of the nervous system, for instance, in cortical (Wang *et al.*, 2012), mesencephalic (Ortiz-Ortiz *et al.*, 2010), spinal cord (Jiang *et al.*, 2011), and hippocampal regions (Ye and Zhang, 2012), due to its antioxidant, anti-inflammatory and anti-protein coagulating properties. Curcumin was reported to reduce the expression of interleukin-1 alpha (IL-1 $\alpha$ ), interleukin-6 (IL-6), and

parts. So the oxidative stress rapidly leads to the hippocampus degeneration, which is the major memory processing region. Such degeneration may lead to the pathogenesis of neurodegenerative diseases including dementia (Liu *et al.*, 2017). The organometal trimethyltin (TMT) has a harmful effect on the brain by enhancing the formation of reactive oxygen species (ROS) in the hippocampus region. TMT also enhances the expression of presenilin, APP, and c-fos (a transcription factor) in the limbic system, which are linked to the pathophysiology of AD. The ethanolic turmeric extract reduces the TMT-induced oxidative stress by decreasing the level of plasma and brain MDA and increases the levels of SOD, glutathione (GHS), CAT, and GPx enzymes in the brain (Yuliani *et al.*, 2019). Curcumin was shown to improve the survival of cortical neurons deprived of oxygen and glucose and concomitant cell injury in an *in vitro* study. Moreover, the results of this study also suggested a decrease in the volume of infarct and oxidative stress following the focal cerebral ischemia in rats (Li *et al.*, 2017). Figure 2 summarizes the neuroprotective effects of curcumin.

tumour necrosis factor- alpha (TNF- $\alpha$ ) in the neurodegenerative disorder due to which the neuro-inflammation decreased (Darvesh *et al.*, 2012; Hatami *et al.*, 2019). The brain cells have high oxygen demand due to which they are more sensitive to oxidative damage. The oxidation of unsaturated fatty acid 4- hydroxy-2,3-nonenal, acrolein, malondialdehyde (MDA) and other compounds as an end product have a negative impact on human health (Ayala *et al.*, 2014). The glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT) are endogenous antioxidant enzymes which protect the cells against oxidative damage due to a high content of unsaturated fatty acids in the brain (Kim *et al.*, 2015). The antioxidant defense system of the brain is weaker as compared to other body

Abbas *et al.* / Food  
Research 4 (6) (2020)  
2366 - 2381




Figure 2. Neuroprotective effects of curcumin

## 7. Role as antioxidant

An antioxidant is a molecule, which, in a concentration lower than its oxidizable substrate, has the ability to substantially retard or delay the substrate oxidation (Galano, 2015). Antioxidants inhibit the catalysis of ROS generation by removing and scavenging the ROS and ROS precursors. Various studies have indicated that brain tissue in dementia patients are exposed to oxidative stress (Liu *et al.*, 2017; Khan *et al.*, 2018). High oxygen demand, terminal neuronal differentiation, and weak antioxidant mechanisms make the central nervous system (CNS) more prone to oxidative stress, which in turn triggers various neurodegenerative disorders (Kim *et al.*, 2015). Several studies have indicated the efficacy of various antioxidants to prevent cognitive decline (Wong *et al.*, 2018), as the treatment options for mild cognitive impairment (MCI) and AD (Mecocci *et al.*, 2004; Cristina Polidori and Nelles, 2014). Age-associated increase in oxidative stress is considered as one of the significant risk factors for cognitive decline (Konar *et al.*, 2016) and is widely thought to be a significant feature in the complexity of AD pathogenicity (Shen *et al.*, 2018). Consequently, there is a growing interest to explore the role of antioxidants in preventing or retarding the initiation of cognitive decline. Generally, an imbalance between the ROS production and the physiological antioxidant defence system is termed as oxidative stress resulting in a shift in the redox state linked to an increased production of ROS which ultimately leads to increased oxidation of lipids, DNA, protein, neurons, and apo E4, all of which are the risk factors for cognitive ageing (Lacour *et al.*, 2017; Legdeur *et al.*, 2018).

### 7.1 Animal studies in mice

Naik *et al.* (2011) studied the antioxidant activity of curcumin at a dosage of 200 mg/kg in Wistar strain rats and reported a correlation of its antioxidant activity with hepatoprotective, anti-inflammatory and cardioprotective effects. Banji *et al.* (2014) have

described that curcumin improved cognition by suppressing the mitochondrial dysfunction and apoptosis induced by D-galactose in rat brains thereby increasing the antioxidant content in neuronal mitochondria. Ciftci *et al.* (2015) have reported the curcumin-mediated prevention of formaldehyde-induced neurotoxicity in rats. Cui *et al.* (2016) have shown that curcumin ameliorated the dopamine-induced neuronal oxidative damage by decreasing the ROS production and increasing the levels of GSH in rat brain cells. Saha *et al.* (2016) reported that curcumin prevented pentylentetrazole (PTZ)-induced neurotoxicity via decreasing the ROS and nitric oxide (NO) levels and increasing the levels of GSH and antioxidant enzymes. Samy *et al.* (2016) have shown that curcumin treatment led to the prevention of AD in streptozotocin (STZ)-induced Alzheimer's dementia in rats by modulating apoptosis and oxidative stress. Sankar *et al.* (2016) reported that curcumin prevented the arsenic-induced neurotoxicity and oxidative damage by decreasing lipid peroxylase (LPO) levels and increasing the levels of GSH and antioxidant enzymes. Waseem and Parvez (2016) reported the preventive effect of curcumin in response to the neurotoxicity and mitochondrial dysfunction induced by oxaliplatin. Sharma *et al.* (2014) have shown that curcumin attenuated the fluoride-induced neurotoxicity and prevented the neurodegeneration by decreasing the level of LPO in the hippocampal region. Nazari *et al.* (2014) reported a neuroprotective effect of highly bioavailable curcumin on sodium nitroprusside-induced oxidative stress model by decreasing oxidative stress.

## 8. Turmeric and Alzheimer's disease

Alzheimer's disease is a widespread disease especially in industrialized western countries. The disease rate is higher in the US and European countries than in Asia (Zhang *et al.*, 2018). In AD, two major lesions are formed: senile plaques and



neurofibrillary tangles (NFT). In senile plaques, dystrophic neurites and activated glial cells are likely to be more central protein deposits of amyloid fibrils that are made up of A $\beta$  peptide (Luchena *et al.*, 2018; Ziegler-Walckirch and Meyer-Luehmann, 2018). Turmeric contains different compounds including curcumin, tetrahydrocurcumin, bisdemethoxycurcumin, and demethoxycurcumin, which act as anti-amyloidogenic by preventing the A $\beta$  protein formation, the pathological root cause of AD (Zhang *et al.*, 2010; Randino *et al.*, 2016). It is stated that a low dose of turmeric (160 ppm) can reduce pro-inflammatory cytokine levels which are linked to the neuroinflammatory cascades involved in the neuritic plaque pathogenicity (Lim *et al.*, 2001). In AD, the faulty phagocytosis occurs due to which A $\beta$  plaques cannot be cleared effectively. Curcumin triggers the phagocytosis due to which the A $\beta$  plaques are cleared *in vitro* and enhance the induction of heat shock protein (HSP) in reaction to the addition of soluble A $\beta$  aggregates to neuronal cell cultures. It also reduces the strength of A $\beta$  amassing and prevents the formation of A $\beta$  fibrils in these cells (Cline *et al.*, 2018; Maiti and Dunbar, 2018). It was suggested that the regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B) activity-associated transcription factors, that is, cytokines and enzymes, was responsible for the therapeutic potential of curcumin in AD (Lee *et al.*, 2013). Epidemiological studies of turmeric show its nonsteroidal anti-inflammatory property, which is linked with reducing the risk of AD (He *et al.*, 2015). Thus, it may be concluded that turmeric increases the neurocognitive function in Alzheimer's patients.

The major active component of turmeric, the curcumin has some interesting properties. It regulates the level of dopamine, norepinephrine, and serotonin in the brain and inhibits the enzyme monoamine oxidase (MAO) A and B, which decompose serotonin and dopamine (Kulkarni *et al.*, 2008; Wang *et al.*, 2014). The role of serotonin is in the neurovegetative function of the body such as sleep, appetite, learning and memory, behaviour, mood, muscle contraction, cardiovascular function and regulation of endocrine, while dopamine is involved in emotion, pleasure and regulating locomotion. A neurotransmitter, norepinephrine, is involved in inattentiveness, sleeping, dreaming, emotion and learning. Turmeric modifies the dysfunction of these neurotransmitters and significantly reduces behavioural symptoms of AD (Zhao *et al.*, 1989; Cole *et al.*, 2004). It is suggested by a clinical study

that curcumin decreases the oxidative damage and removes the stimulus for A $\beta$  formation. It also reduces the inflammation in microglial cells of the brain by reducing the cytokines level which is pro-inflammatory signalling molecules and by preventing the formation of A $\beta$ , thereby decreasing the A $\beta$  plaques. It generates an enzyme which reduces the risk of A $\beta$  production and lowers the oxidation of those fats and proteins which are dangerous. It triggers the macrophage cells of the brain to clear the A $\beta$  plaques which are already present. It inhibits A $\beta$  aggregation and reverses the neurodegeneration due to A $\beta$  production and also inhibits the A $\beta$  mediated neurotoxicity. It also blocks the cholesterol formation that is also a factor involved in the formation of A $\beta$  (Tang and Taghibiglou, 2017).

In an *in-vitro* study, it was shown that curcumin has the ability to reduce the number of plaques in the brain by impeding A $\beta$  plaques formation (Ahmed and Gilani, 2014). The higher concentration of curcumin at the molecular level binds to A $\beta$  to block self-assembly. As curcumin is lipophilic in nature, it easily crosses the blood-brain barrier (BBB) and then binds to the A $\beta$  plaques. Curcumin has metal chelating property as it has the ability to bind with the metal ions and improve the A $\beta$  degradation and decreases the oxidative stress (Maiti and Dunbar, 2018; Reddy *et al.*, 2018). It binds with iron, copper with high affinity rather than zinc thereby acting as a protector against AD, and may protect against iron-mediated damage (Tang and Taghibiglou, 2017). A decreased serum A $\beta$  level along with a reduction in A $\beta$  burden in the brain, that was more prominent in the regions of neocortex and hippocampus, resulted after the administration of curcumin to an AD mouse model (Farooqui *et al.*, 2018; Wang *et al.*, 2012). These studies highlight the promising role of turmeric and curcumin in the inhibition of A $\beta$  plaques formation and, hence, their ability to improve the neurodegenerative disease condition.

### 8.1 Animal studies in mice

Dohare *et al.* (2008) studied the neuroprotective activity of Curcuma oil (250 mg/kg) in Sprague-Dawley male rats and reported that Curcuma oil promoted the suppression of increasing intracellular concentration of Ca<sup>2+</sup> that is considered as an important player in different signalling pathways. They also reported that the curcuma oil caused a decrease in ROS generation leading to the prevention of brain neutrophils and NO metabolites infiltration following ischemia in the brain. The neuroprotective



activity of curcumin in Sprague-Dawley male rats at a dosage of 300 mg/kg was also reported by Dohare et al. (2008) also reported that curcumin-induced selective inhibition of neuronal

stated that curcumin treatment significantly attenuated the increased volumes of brain infarct and edema following ischemia in rats. Zhang *et al.* (2008) investigated the neuroprotective activity of curcuminoids (1-10  $\mu\text{mol}$ ) in newborn Sprague-Dawley rats and revealed that curcuminoids significantly suppressed the NO production by LPS-activated microglia in rat brain. Jayanarayanan *et al.* (2013) described the neuroprotective activity of curcumin in STZ-induced Wistar male rats at a dosage of 60 mg/kg and reported the beneficial effect of curcumin supplementation to STZ-induced diabetic rats thereby reducing the alterations in glutamatergic receptors, imbalanced glutamate metabolism, and oxidative stress. Eckert *et al.* (2013) reported the effect of curcumin on mitochondrial dysfunction in brain of male Senescence Accelerated Mouse Prone-Strain 8 (SAMP8) and Senescence Accelerated Mouse Resistant-Strain 1 (SAMR1) at a dosage of 500 mg/kg and observed a significant decrease in mitochondrial dysfunction and energy production in the brain cells of SAMP8 mice. Chen *et al.* (2014) studied the neuroprotective activity of curcumin at a dosage of 500 nmol/L in Sprague-Dawley female rats (pregnant for 14.5 days) and reported that the neuroprotective effect of curcumin was through upregulation of wnt3a and  $\beta$ -catenin expression in the control experimental group receiving curcumin at a dose of 500 nmol/L. Gazal *et al.* (2014) described that pretreatment of a ketamine-induced model of mania in female adult Wistar rats with curcumin led to the prevention of ketamine-induced behavioral and prooxidant effects. Ahmed and Gilani (2009) studied the anti-AD effects of curcuminoids and its individual components at a dosage range of 3-10 mg/kg in Sprague-Dawley male rats and reported their memory enhancing capacity in addition to the dose-dependent inhibitory effect in frontal cortex and hippocampus as well as *ex vivo* acetylcholinesterase assay. Ahmed *et al.* (2010) described that the anti-AD effect of curcuminoids and its individual components at a dosage range of 3-10 mg/kg in A $\beta$  peptide-infused Sprague-Dawley male rats was due to the curcuminoids-mediated increased expression of synaptophysin. These data suggest the importance of diet supplemented with curcumin as a preventive measure and treatment option for AD that may decrease A $\beta$  and plaque burden in addition to lowering the oxidative stress in the brain.

Some investigations regarding the preclinical trials to test the efficacy of curcumin in humans along with the pharmacokinetics and safety have been reported in the literature. The oral administration of curcumin in twenty-five patients of neurodegenerative diseases at a dose range of 500-8000 mg (1.36-2.17 mmol/day) for a period of three months was reported to have no noticeable toxicity (Hsieh, 2001). In another preclinical study, the oral administration of curcumin in 24 healthy volunteers at a single dose ranging from 500 to 12000 mg (1.36- 32.6 mmol) resulted in dose-independent minimal toxicity in 30% volunteers. This study concluded that curcumin could be safely administered to patients at a single dose of 12 grams, and up to 8 grams per day for a period of three months (Lao *et al.*, 2006). Baum *et al.* (2008) performed a double-blind, randomized, placebo-controlled study on 34 AD patients. The participants were randomly assigned for oral administration of curcumin at two different doses from 1 or 4 g or placebo at a dose of 4 g. The study revealed that there was no improvement in the Mini-Mental State Examination (MMSE) score that assesses the mental status after curcumin treatment. Moreover, there was no effect of curcumin treatment on the level of serum A $\beta_{40}$ . However, curcumin treatment was found in association with an increase in vitamin E level, without any adverse side effects. It was concluded that the increase in the level of vitamin E might be in response to the antioxidant activity of curcuminoids leading to a decrease in the need for antioxidant vitamin E. Lopresti *et al.* (2014) conducted a randomized, double-blind, and placebo-controlled study on human subjects aged 18 to 65 and reported a more significant effect of curcumin than placebo on the improvement of several mood-related symptoms. It may be inferred from these studies that there is a need to open a clinical trial of curcumin against AD based on a large number of patients.

## 9. Therapeutic role in Parkinson's disease

Parkinson's disease is another prevalent age-related neurodegenerative condition. It is associated with selective exposure to the neuromelanin containing dopaminergic neurons pars compacta region of the substantia nigra of the midbrain and their terminals in the striatum. In PD, the death of dopaminergic neurons occurs in this region and the symptoms of PD can't be recognized until 60–80% of



neurons are lost. Among the age-related neurodegenerative disorders, PD is strongly associated with an increased rate of oxidative damage. It is also linked with the auto-oxidative breakdown of dopamine and metabolism of semiquinone to superoxides (Blesa *et al.*, 2015; Magalingam *et al.*, 2015; Maiti *et al.*, 2017). Turmeric has antioxidant and anti-inflammatory properties which help in PD as the studies show that turmeric is helpful in preventing the chronic inflammation that causes the neurodegeneration and brain cell malfunctioning. Many conditions are included in association with metabolic disorders like diabetes, high cholesterol level, insulin resistance, hypertension,



fatty liver, and psychological stress (Hewlings and Kalman, 2017; Abdel-Salam, 2019). Turmeric contains resveratrol, quercetin and vitamin C which can assist to conduct heme oxygenase-1 (HO-1) production. Curcumin enhances the response against heat shock and also stimulates the vitagenes HO-1 and Hsp-70. Due to this effect of curcumin, the body enhances the production of its own antioxidants which help to defend the brain against free radical damage. According to some reports, excessive HO-1 can deposit iron in those cells which are damaged in PD, however, animal studies show that only the protective amounts are induced by curcumin. In vitro studies have shown that curcumin enhances the body's effective natural antioxidant enzyme, superoxide dismutase (Mazzio *et al.*, 2011; Kim *et al.*, 2016; Yang *et al.*, 2017; Abdel-Salam, 2019).

A low dose of curcumin was reported to inhibit the toxicity of dopamine *in vivo* (Luo *et al.*, 1999; Maiti *et al.*, 2017). The oxidative damage to selective dopaminergic neuron and consequent PD can be produced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) toxins in human and animal models showing the defect in complex I of mitochondrial electron transport chain as well as an increase in the production of free radicals in brain and peripherals region are also identified (Mehlhorn and Cole, 1985; Dias *et al.*, 2013; Subramaniam and Chesselet, 2013). The toxicity of MPTP is mediated by MPP<sup>+</sup>, and toxicity of MPP<sup>+</sup> to the neuronal cell line PC12 is inhibited by curcumin and cyclocurcumin (Chakraborty *et al.*, 2017). The aggregation of fibre-forming protein, that is,  $\alpha$ -synuclein is a major part of LB lesions that is the characteristics of PD as well as AD, and other neurological disorders (Melki, 2015).

The clinical application of curcumin is strongly supported in PD through several studies. According to Song *et al.* (2016), curcumin is a promising applicant for PD as it improves the neuro functions of substantia nigra neurons by regulating intracellular expressions of SOD, NGF, GSH, and Hsp70. Gadad *et al.* (2012) showed that curcumin inhibited additional fibrillization of  $\alpha$ -synuclein by binding with the  $\alpha$ -synuclein oligomer. Phom *et al.* (2014) reported that curcumin refreshes the consumed dopamine level in early PD while its effect is limited as a therapeutic agent in the later stages. Curcumin was shown to reverse the decrease in the levels of dopamine and its metabolite 3, 4-dihydroxyphenylacetic levels induced by

hydroxydopamine (6-OHDA) in the striatum. Furthermore, curcumin was able to restore the concentration of tyrosine hydroxylase-positive neurons along with a decrease in the concentration of iron-positive cells in comparison with the control group treated with 6-OHDA. Curcumin was reported to attenuate the neurotoxin-triggered loss of striatal dopamine axons at the same dose for seven days following post 6-OHDA injection. The neuroprotective activity of curcumin has been attributed to the inhibition of astroglial and microglial reaction, as indicated by a decreased levels of glial fibrillary acidic protein and immunoreactivity of ionized calcium-binding adapter molecule 1, in addition to maintaining the level of superoxide dismutase 1 (Kujawska and Jodynis-Liebert, 2018).

## 10. Conclusion

11. In Southeast Asia, turmeric is widely used as a coloring agent and spice. Since ancient times, it has also been used in conventional medical systems. There are many therapeutic uses for turmeric and its constituents. Turmeric's primary ingredient, curcumin, is a pleiotropic compound with anti-inflammatory and antioxidant qualities. These characteristics have led to the use of turmeric and curcumin as neuroprotective medicines in neurodegenerative diseases, including AD and PD. The nutraceutical method, which uses a safe and affordable substance like curcumin, may create a new path for the management and treatment of neurodegenerative illnesses like AD and PD, since presently available pharmacological options have shown limited effectiveness and many adverse effects. However, one of the main obstacles to using curcumin as a nutraceutical therapy for neurodegenerative illnesses is its low bioavailability. Several approaches that include chemical modification or co-administration of curcumin with substances that can promote its absorption can address this problem. Despite some encouraging indications about curcumin's effectiveness in treating neurodegenerative illnesses, scientific studies have not shown solid proof that curcumin may effectively cure these conditions. Thoroughly planned large-scale clinical studies and preventative measures are necessary to determine curcumin's



effectiveness in neurodegenerative diseases like AD and PD.

## References

- O.M. Abdel-Salam (2019). Use of Alternative Medicines and Herbal Products in Neurodegenerative Diseases (Parkinson's and Alzheimer's). Joshi, N. and Singh, S. (Eds). Neurodegenerative Disease Pathology, Prevention, and Treatment, pp. 279–301. Springer, Singapore. 10.1007/978-981-13-0944-1\_24 via <https://doi.org>
- Hassan, S., Kormin, F., Sabran, S.F., Hassan, S., Abu Bakar, F., Abu Bakar, M.F., and Fuzi, S. (2020). *Sonneratia caseolaris* fruit, both ripe and unripe, were compared for phytochemicals, antioxidants, and anti-cholinesterase activity. 507–514, *Food Research*, 4(2). 2017.4(2).277 <https://doi.org/10.26656/fr>.
- Shukla, R., Tyagi, E., Nath, C., Mishra, B., and Agrawal, R. (2010). Impact of curcumin on insulin receptors in the brain and memory in a rat model of dementia caused by STZ (ICV). 247–252 in *Pharmacological Research*, 61(3). j.phrs.2009.12.008 <https://doi.org/10.1016>
- Gilani, A., Ahmed, T., and Enam, S. (2010). In a rat model of Alzheimer's disease where amyloid has been injected, curcuminoids improve memory. 169(3), *Neuroscience*, 1296-1306. 1016/j.neuroscience.2010.05.078 <https://doi.org>
- Gilani, A.-H. and Ahmed, T. (2009). Turmeric's therapeutic effectiveness in Alzheimer's disease may be explained by its inhibitory impact on acetylcholinesterase activity and its ability to reduce scopolamine-induced forgetfulness. *Biochemistry and Behavior in Pharmacology*, 91(4), 554-559. j.pbb. <https://doi.org/10.1016>. 09.010 (2008)
- Gilani, A.H. and Ahmed, T. (2014). Does turmeric include curcumin or curcuminoids that have therapeutic promise for Alzheimer's disease? *Research on Phytotherapy*, 28(4), 517-525. ptr.5030 <https://doi.org/10.1002/>
- T.A. Ajith (2018). A new report on how omega-3 fatty acids affect Alzheimer's disease. 13(4), 252-260, *Current Clinical Pharmacology*. 10.2174/1574884713666180807145648 <https://doi.org/10.2174>
- Singh, S., Patnaik, J., Akbar, A., Kuanar, A., Sandeep, I., Kar, B., Mohanty, S., and Nayak, S. (2015). Some genotypes of turmeric (*Curcuma longa* L.) with significant drug yields were subjected to GC-MS investigation of their essential oil. *Pharmaceutical Sciences and Pharmacy International*, 7(9), 35–40. Gopi, S., Amalraj, A., and Pius, A. (2017). An overview of the biological properties of curcuminoids, other biomolecules found in turmeric, and their derivatives. 7(2), 205-233, *Journal of Traditional and Complementary Medicine*. 10.1016/j.jtcme.2016.05.005 at <https://doi.org>
- Newman, R.A., Aggarwal, B.B., Kunnumakkara, A.B., and Anand, P. (2007). Curcumin's bioavailability: issues and opportunities. 807-818 in *Molecular Pharmaceutics*, 4 (6). The article <https://doi.org/10.1021/mp700113r>
- Prakash, O., Verma, A., Pant, A., and Arya, N. (2015). *Curcuma longa* L. obtained from several ecological niches in the Western Himalayan area exhibited varying antioxidant activity. *Pharmaceutical Sciences, International Journal of Pharmacy*, 7(7), 85-90.
- Yeoh, T., Bhat, R., and Azmi, N.S. (2016). Assessment of the quality of new cookies made using fresh extracts from turmeric flowers (*Curcuma longa* L.) as a functional ingredient that adds value. *Journal of International Food Research*, 23(4), 1514-1522.
- Ch, K., Banji, D., and Banji, O.J. (2014). By preventing D-galactose-induced apoptosis and mitochondrial dysfunction in the rat brain, curcumin and hesperidin enhance cognition. *Chemical and Food Toxicology*, 74, 51–59. j.fct.2014.08.020 10.1016 <https://doi.org>
- Tsoh, J., Lam, L., Leung, V., Hui, E., Ng, C., Lam, C.W.K., Cheung, S.K.-K., Kwok, T., and Lui, V. (2008). Curcumin in Alzheimer disease patients: a six-month randomized, double-blind, placebo-controlled pilot study. *Clinical Psychopharmacology Journal*, 28(1), 110–113. 10.1097/jcp.0b013e318160862c <https://doi.org>
- Jackson-Lewis, V.R., Quiroga-Varela, A., Trigo-Damas, I., and Blesa, J. (2015). Parkinson's disease and oxidative stress. *Neuroanatomy Frontiers*, 9, 91. 10.3389/fnana.2015.00091 (10.doi.org) Tsai, J.-W., Karmenyan, A., Chakraborty, S., and Chiou, A. (2017). Curcumin and cyclocurcumin's inhibitory effects on 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity in PC12 cells that have undergone differentiation. 16977 in *Scientific Reports*, 7(1). 10.1038/s41598-017-17268-3 <https://doi.org>
- Chen, F., Yuan, J., Chu, W., Xue, X., Zhu, H.,



Ge, H., Zou, M., Wang, H., Xiang, X., Yuan, J.,  
and Feng, H. (2014).

Through wnt signaling, curcumin accelerated the  
rate of neuronal development in neural stem cells  
in an in vitro research. 192(2), 298-304, Journal  
of Surgical Research. 10.1016/j.jss.2014.06.026  
<https://doi.org>

Chen, H., Zhang, M., Xu, W., Huang, G., Liu, S.,  
Ji, L., Wu, T., Ji, Y., Zhou, Y., Zheng, M., and  
Zhang, M. (2016). Folic